441 related articles for article (PubMed ID: 16554162)
1. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
3. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.
Desbene S; Van HD; Michel S; Tillequin F; Koch M; Schmidt F; Florent JC; Monneret C; Straub R; Czech J; Gerken M; Bosslet K
Anticancer Drug Des; 1999 Apr; 14(2):93-106. PubMed ID: 10405636
[TBL] [Abstract][Full Text] [Related]
4. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
Wang Y; Xin D; Liu K; Zhu M; Xiang J
Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological activity of protaxols.
Nicolaou KC; Riemer C; Kerr MA; Rideout D; Wrasidlo W
Nature; 1993 Jul; 364(6436):464-6. PubMed ID: 8101355
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
de Groot FM; van Berkom LW; Scheeren HW
J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
[TBL] [Abstract][Full Text] [Related]
8. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
9. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy.
Thomas M; Rivault F; Tranoy-Opalinski I; Roche J; Gesson JP; Papot S
Bioorg Med Chem Lett; 2007 Feb; 17(4):983-6. PubMed ID: 17157009
[TBL] [Abstract][Full Text] [Related]
11. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
12. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness.
Greenwald RB; Gilbert CW; Pendri A; Conover CD; Xia J; Martinez A
J Med Chem; 1996 Jan; 39(2):424-31. PubMed ID: 8558510
[TBL] [Abstract][Full Text] [Related]
13. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
14. A new paclitaxel prodrug for use in ADEPT strategy.
Bouvier E; Thirot S; Schmidt F; Monneret C
Org Biomol Chem; 2003 Oct; 1(19):3343-52. PubMed ID: 14584798
[TBL] [Abstract][Full Text] [Related]
15. A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.
Grinda M; Clarhaut J; Tranoy-Opalinski I; Renoux B; Monvoisin A; Cronier L; Papot S
ChemMedChem; 2011 Dec; 6(12):2137-41. PubMed ID: 21815268
[No Abstract] [Full Text] [Related]
16. Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT.
Kamal A; Tekumalla V; Krishnan A; Pal-Bhadra M; Bhadra U
ChemMedChem; 2008 May; 3(5):794-802. PubMed ID: 18247436
[TBL] [Abstract][Full Text] [Related]
17. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
18. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel.
Hayashi Y; Skwarczynski M; Hamada Y; Sohma Y; Kimura T; Kiso Y
J Med Chem; 2003 Aug; 46(18):3782-4. PubMed ID: 12930140
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT.
de Bont DB; Leenders RG; Haisma HJ; van der Meulen-Muileman I; Scheeren HW
Bioorg Med Chem; 1997 Feb; 5(2):405-14. PubMed ID: 9061205
[TBL] [Abstract][Full Text] [Related]
20. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]